Losartan Potassium Tablet, Film Coated
Product Images NDC 71205-598

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71205-598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure diagram of the active ingredient Losartan Potassium. The diagram shows connectivity between atoms including carbon, nitrogen, chlorine, and potassium ions, representing the molecular composition of Losartan Potassium.*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period for Atenolol (dotted line) and Losartan potassium (solid line). The graph shows a lower cumulative percentage for Losartan potassium, with an adjusted risk reduction of 13% (p=0.021), indicating comparative patient outcomes over time.*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over time between Atenolol and Losartan potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients up to 8%. Atenolol is displayed with a dotted line, and Losartan potassium with a solid line, indicating a lower stroke percentage in the Losartan potassium group, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A forest plot chart comparing event rates and hazard ratios for Losartan Potassium versus Atenolol in primary composite outcomes and stroke (fatal/non-fatal) across different patient subgroups, including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The chart visualizes hazard ratios with confidence intervals and indicates which treatment is favored.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A Kaplan-Meier curve showing the percentage of patients with an event over 48 months. The graph compares Losartan potassium (solid line) and placebo (dotted line) groups, indicating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

71205-598-90 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 11)

LOSARTAN POTASSIUM 50 mg film-coated tablet label from Proficient Rx LP. The label indicates a quantity of 90 tablets. Tablets are white, round, biconvex, with '12' debossed on one side. Manufactured by Vivimed Life Sciences Private Limited in India. Includes packaging and lot information, storage instructions, and warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.